TruScreen Optical-Electrical Technology was born in the late 1980s, by a group of leading Professors, Doctors, and Experts (Sydney University) in the field of Gynecological Oncology, researching and coordinating to develop technological algorithms with the University of Sydney. CSIRO (part of the Australian government).
TruScreen®ULTRA device is a cervical cancer screening device according to European standards, applying new technology - Photoelectric technique and used as a first-line screening tool, to identify pre-cancerous lesions. cancer and cervical cancer or cervical intraepithelial neoplasia (CIN) as feedback signal information and encoded by direct Spectrophotometric and Voltage measurements on cervical tissue .
After collecting the response signal, the device uses a comparison algorithm to process the data and produce real-time results.
In addition to operating independently as a first-line rapid screening tool, with high sensitivity and standard specificity, TruScreen® ULTRA effectively and efficiently supports doctors and patients in cancer screening. Cervical cancer in just one visit.
text 1
text 2
text 3
text 4
TruScreen®ULTRA is the only device in the world that combines two optical and electrical principles to identify abnormalities. This is also the factor that helps TruScreen®ULTRA have very high sensitivity in screening for cervical cell tissue damage.
The TruScreen device uses Spectroscopic analysis technology with 4 light beams to transmit signals to the Cervical epithelium. The light wavelengths not only examine the surface epithelial layer of the cervix but also go deep into the basal layers and stromal tissue for examination. Changes in the cell nucleus due to cancer will directly affect the transmitted light signal.
With Resistance measurement analysis technology, TruScreen ULTRA delivers extremely low electrical pulses to the cervical surface (average voltage level 0.8 volts / 350ms) due to the capacitive decay reaction of the tissue. Depending on the characteristics of normal and abnormal tissue, the response signal will be different electrical decay curves.
After the signal is reflected from the Spectroscopy and Resistance measurement, the device uses a pre-programmed and built-in AI algorithm to process the received signals. The algorithm analyzes signals and classifies tissues by comparing input signals with more than 2000 stored sample tissue samples available in the “Multicenter Mass Data – Database”. From there, TruScreen® determines “Normal” and “Abnormal” tissue status (Precancerous lesions, cancer or cervical intraepithelial neoplasia (CIN)).
In one study, data confirmed TruScreen to have high sensitivity for 75 – 86% and specificity for 75 – 82%. Applying Photoelectric technology, the TruScreen method helps detect early and effectively potential malignant cells located in the layers below the epithelium, minimizing the possibility of missing the disease.
TruScreen results are analyzed from the automation system through pre-programmed algorithms from multi-center data blocks, so TruScreen results are objective and do not depend on human factors.
Results are analyzed in real-time, so patients are provided with results immediately without waiting time.
With immediate results, patients are promptly monitored and receive medical advice and treatment appropriate to their health condition.
TruScreen screening method is a non-invasive method, without taking samples for testing like other traditional methods. Patients do not feel pain or discomfort, showing that TruScreen cervical cancer screening completely reduces pressure and anxiety for women when coming for examination. This makes patients willing to return for regular health check-ups and monitoring.
TruScreen is a portable device that facilitates transportation and is easy to operate and use. Therefore, with this new technology, medical facilities save training costs and do not need to invest in infrastructure or standard laboratories. Doctors can easily manipulate and use it to examine patients. Not only that, the convenience of TruScreen especially helps women from all walks of life have closer access to health care.
GHS Company focuses on providing clinicians, medical centers and leading agencies in the field of Vietnamese public health with an effective solution to help improve the early diagnosis rate of cancer. cervical level to a safe level compared to developed countries without costly training and education costs.
On the other hand, women will also benefit from the Cervical Cancer Screening Program using the Truscreen method. With the ability to minimize invasiveness and examination pressure, this method also provides immediate results in just one visit.
That is why GHS Company decided to develop Truscreen products in Vietnam with the desire to reduce the burden caused by cervical cancer and contribute to improving the quality of life of women in particular and society. association in general.
Truscreen is a new method and completely new technique, so it needs permission from the Ministry of Health to be applied in Vietnam. Up to now, we have implemented and completed the processes for the Truscreen device to be officially used in Vietnam.
